HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce important updates to its partnership efforts. Dosing of the first patient in a Phase 1 trial in the US for AV-P138-ADC (ARR-002) was recently announced by Aarvik’s research collaboration partner, ArriVent Biopharma, Inc. (ArriVent; Nasdaq: AVBP). AV-P138-ADC (ARR-002) is the first MUTTA™-based ADC
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
